JNJ Jan 2025 240.000 put
| Previous Close | 93.33 |
| Open | 93.33 |
| Bid | 91.85 |
| Ask | 95.65 |
| Strike | 240.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 93.33 - 93.33 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksWhy Johnson & Johnson (JNJ) Dipped More Than Broader Market Today
Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.
PR NewswireERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA® (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). Presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon, Portugal, on October 2 (Abstract #P31), this study of nearly 4,000 patients represents the largest real-world
ReutersJ&J to invest over $2 billion for new manufacturing facility in North Carolina
The new facility will expand J&J's production of biologic medicines to treat cancer, immunity-related and neurological diseases, the company said. The drugmaker aims to launch or file for more than 70 new therapies and expanded treatment options for patients by 2030. J&J is investing in capacity to ensure a resilient supply chain for the future, said Dapo Ajayi, vice president at J&J's innovative medicine supply chain.
